DXM administration increases time spent in the wake state and decreases that in NREM sleep. by Tomonobu Kato (17684578)

Behavioral deficits correlate with decreasing PO₂ in cortical grey matter. by Thomas W. Johnson (437931)

Decreased Levels of Sod1 Protein in <i>Fmr1</i> Null Cells, Brain, and Embryos by Elias G Bechara (267911)

“…On the right, corresponding densitometric analyses show a significant decrease of <i>Sod1</i> expression, after comparing five wild-type rescued clones and five <i>FMR1</i> knockout clones. …”

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Mean decrease accuracy plots and variable importance plots for the random forest classification process of clusters 1 and 2 in study regions North and South (<i>F</i>. <i>hepatica<... by Andreas W. Oehm (12015558)

“…<p>A: study region North. B: study region South. The mean decrease accuracy plot expresses how much accuracy the model loses by excluding each variable. …”

Fenretinide decreases levels of PAX3/FOXO1 and its target genes in aRMS cell lines. by David Herrero Martín (286820)

“…<p>Rh4 and RMS13 cells were treated for 24 hours (A) and 48 hours (B) with different concentrations of fenretinide (0.5–1–5 µM, as indicated). …”

CK-B_C283S Decreases Actin Accumulation in Phagocytic Cups by Jan W. P Kuiper (42786)

ASO treatment suppresses the palbociclib-mediated induction of MEG3 and decrease in cell proliferation in A549 cells. by Traci L. Kruer (3342425)

Tethered HP1 Decreases Histone Acetylation throughout the ψVλ Array by W. Jason Cummings (9607)

Knockdown of HIF-1α decreases osteolytic lesions and improves survival of mice <i>in vivo</i>. by Lauren K. Dunn (260121)

Inactivation of Rb leads to decreased expression of MEG3 and re-expression inhibits proliferation in A549 cells. by Traci L. Kruer (3342425)

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

Subjects:

WT data of set A398E/V and set M1425V/I pooled for better comparison. by Yousra El Ghaleb (22075892)

Subjects:

CHNRI's conceptual framework showing key steps required to get from investments in health research options to decrease in burden of death, disease, or disability. by Igor Rudan (150101)

PowerPoint Slides for: Patiromer Decreases Serum Potassium and Phosphate Levels in Patients on Hemodialysis by Bushinsky D.A. (3246690)

“…<p><b><i>Background:</i></b> Persistent hyperkalemia (serum potassium (K) ≥5.5 mEq/l) is a common condition in hemodialysis (HD) patients, is associated with increased mortality, and treatment options are limited. …”

AAV-mediated Atp6v1c1 knockdown decreased TRAP positive cells and Atp6v1c1 expression in the periodontitis lesion area. by Sheng Li (107261)

“…<p>(A) TRAP staining was used to indicate the decrease in Atp6v1c1 expression in periodontal tissues after AAV-sh-Atp6v1c1 knockdown. …”